Bronwyn Brophy is appointed new CEO of Vitrolife AB (publ)
Rhea-AI Summary
Bronwyn Brophy has been appointed as the new CEO of Vitrolife (OTC-PINK:VTRLY), starting August 1, 2023. Brophy brings substantial leadership experience from previous roles at Thermo Fisher Scientific, Medtronic, and Johnson & Johnson. She will replace Thomas Axelsson, who will step down on March 31, 2023, with Jón Sigurdsson serving as interim CEO until Brophy's arrival. The board expects Brophy's experience will drive growth and enhance shareholder value. Sigurdsson praised her international experience as vital for the company’s future.
Positive
- Bronwyn Brophy's extensive leadership experience in Life Science and Medtech.
- Her appointment is seen as a strategic move to enhance shareholder value.
Negative
- Concerns regarding leadership continuity during the transition period.
News Market Reaction
On the day this news was published, VTRLY declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
As notified
Jón Sigurdsson, chairman of the board, says: "I am very pleased that we have been able to assign
Contact persons:
This information is information that
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
The following files are available for download:
View original content:https://www.prnewswire.com/news-releases/bronwyn-brophy-is-appointed-new-ceo-of-vitrolife-ab-publ-301735771.html
SOURCE